About Epizyme
Epizyme is a Healthcare company based in Cambridge (United States) founded in 2007. Epigenetic treatment solutions for cancer are provided. Epizyme has raised $51.5 million across 6 funding rounds from investors including Kleiner Perkins, Royalty Pharma and Celgene. Its Indian entity Thar Commercial Finance Private Limited reported revenue of ₹55.98 Cr. The company has since been acquired. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Insitro, BridgeBio and C4 Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Epizyme was founded in 2007 and is based in Cambridge, United States. Operations focus on the biotechnology sector, where epigenetic therapies for cancer are developed. Lead candidates include TAZVERIK, approved for epithelioid sarcoma and follicular lymphoma, along with a protein arginine methyltransferase inhibitor targeted at solid tumors and blood cancers. Research and development efforts are centered on advancing these oncology solutions.
- Headquarters Cambridge, United States
- Stage Acquired
- SectorsHealthcare
- Website epizyme.com
- Social LinkedIn X
- Legal Name Epizyme, Inc.
- Date of Incorporation 25 Jul, 2008
- Jurisdiction Mumbai, Maharashtra, India
- Indian entity revenue₹55.98 Cr
FY 2025 · +7% YoY
- Indian entity net profit₹5.93 Cr
FY 2025 · 11% margin
- Indian entity EBITDA₹48.21 Cr
FY 2025 · 86% margin
- Total Equity Funding$51.5M (USD)
in 6 rounds
- Latest Funding Round$270M (USD), Post-IPO
Nov 2019
- InvestorsKleiner Perkins
& 10 more
Associated legal entities of Epizyme
Epizyme operates through Thar Commercial Finance Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Thar Commercial Finance Private Limited CIN U65999MH2008PTC185082 | Active | 25 Jul 2008 | Mumbai, Maharashtra | ₹56.0 Cr | 4 | View details |
Funding Insights of Epizyme
Epizyme has successfully raised a total of $51.5M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $270 million completed in November 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $51.5M
- Total Rounds 6
- Last Round Post-IPO — $270M
- First Round $32M
(Oct 2009)
- Investors Count 11
All 6 funding rounds of Epizyme with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2019 | $270M | Post-IPO | – | – | |
| Feb 2014 | $10M | Post-IPO | – | – | |
| Oct 2011 | $4M | Series B | – | – | |
| Jun 2011 | $7.5M | Series B | – | – | |
| Dec 2009 | $8M | Series B | – | – | |
| Oct 2009 | $32M | Series B | – | Bay City Capital |
11 investors in total: 11 institutional.
Investors in Epizyme
Epizyme has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, Royalty Pharma and Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in marketed and late-stage biopharmaceutical companies. | 1996 | royaltypharma.com | New York, United States | |
Investment management services are provided to the life sciences industry. | pharmakonadvisors.com | New York, United States | ||
Research and patient support for blood cancers are funded. | 1949 | lls.org | Rye Brook, United States | |
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Stage-agnostic investments in US life-sciences sectors are managed. | baycitycapital.com | San Francisco, United States | ||
| astellasventure.com | ||||
Venture capital investments are facilitated by Amgen-backed entity. | amgenbd.com | Thousand Oaks, United States | ||
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States | |
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States | |
Developer of pharmaceuticals and vaccines for various therapeutic areas | 1715 | gsk.com | Brentford, United Kingdom |
Investor details for Epizyme
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Thar Commercial Finance Private Limited (Epizyme)
Thar Commercial Finance Private Limited is the primary company behind Epizyme. The board of Thar Commercial Finance Private Limited currently have 3 directors; the longest-serving is Vivek Jayesh Thar, appointed in 2015. 11 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vivek Jayesh Thar DIN 06812365 | Director | 21 Feb 2015 | 11 yrs 8 mo | Thar Commercial Finance Private Limited |
| Chintan Hitendra Shah DIN 01376629 | Director | 21 Jan 2019 | 7 yrs 9 mo | Thar Commercial Finance Private Limited |
| Yatin Ajitrai Mankad DIN 00786683 | Director | 10 May 2021 | 5 yrs 6 mo | Thar Commercial Finance Private Limited |
People of Epizyme
17 people are tracked at Epizyme (5 in leadership, 9 in board & advisors, 3 in team).
| Name | Role | Group |
|---|---|---|
Tanja Weber | Chief Business Officer | Leadership |
Jeffery Kutok | Chief Scientific Officer | Leadership |
Grant Bogle | President & CEO | Leadership |
Shefali Agarwal | EVP & Chief Medical & Development Officer | Leadership |
Rebecca Mehrwerth | SVP & Head, Commercial | Leadership |
Victoria Richon | Board Member | Board & advisors |
Pablo Legorreta | Board Member | Board & advisors |
David M. Mott | Chairman | Board & advisors |
Michael F. Giordano | Board Member | Board & advisors |
Carl Goldfischer | Board Member | Board & advisors |
Ken Bate | Board Member | Board & advisors |
Roy A. Beveridge | Board Member | Board & advisors |
Carol Stuckley | Board Member | Board & advisors |
Kevin T. Conroy | Board Member | Board & advisors |
Jennifer Schmitke | SVP, Technical Operations & Quality, Portfolio & Program Management | Team |
Apoorva Kapopara | Clinical Research Scientist | Team |
John Weidenbruch | General Counsel | Team |
Complete people profiles for Epizyme
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Epizyme
Figures of Thar Commercial Finance Private Limited, the primary company behind Epizyme, for FY 2025. Revenue was ₹55.98 Cr (+7% year on year). Net profit was ₹5.93 Cr (11% margin). EBITDA was ₹48.21 Cr (86% margin). Revenue has grown at a compounded annual rate of +9% over three years and 0% over five years.
- ₹55.98 CrRevenue · FY 2025 · +7% YoY
- ₹5.93 CrNet profit · 11% margin
- ₹48.21 CrEBITDA · 86% margin
- ₹49.96 CrPaid-up capital
- +9%Revenue CAGR, 3 years
- 0%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Thar Commercial Finance Private Limited are on its company page.
Detailed financial statements for Epizyme
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Epizyme
4 dated milestones of Epizyme across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Epizyme is founded.
- Funding First funding round of $32.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $270.0M.
Competitors of Epizyme
Epizyme has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and C4 Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Epizyme
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Epizyme
Websites that share an audience with Epizyme (epizyme.com).
Websites whose visitors overlap most with Epizyme. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| agios.com | 100% | 21.8K | #1,284,134 | View details | |
| bluebirdbio.com | 99% | 9.1K | #3,210,476 | View details | |
| constellationpharma.com | 85% | View details | |||
| acceleronpharma.com | 83% | View details | |||
| oncomed.com | 78% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for Epizyme
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Epizyme (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Epizyme
Complete news archive for Epizyme
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Epizyme
Epizyme was founded in 2007 and raised its 1st funding round 2 years after it was founded.
Epizyme is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Epizyme is a funded company, having raised a total of $51.5M across 6 funding rounds to date. The company's 1st funding round was a Series B of $32M, raised on Oct 2009.
The primary company behind Epizyme, Thar Commercial Finance Private Limited, reported revenue of ₹55.98 Cr for FY 2025, up 7% year on year.
Epizyme was founded in 2007 and is based in Cambridge, United States. Operations focus on the biotechnology sector, where epigenetic therapies for cancer are developed. Lead candidates include TAZVERIK, approved for epithelioid sarcoma and follicular lymphoma, along with a protein arginine methyltransferase inhibitor targeted at solid tumors and blood cancers. Research and development efforts are centered on advancing these oncology solutions.
Epizyme's top competitors include BridgeBio, C4 Therapeutics and Insitro.
Epizyme has 11 investors. Key investors include Kleiner Perkins, Royalty Pharma, Celgene, GSK, and Leukemia & Lymphoma Society.
Epizyme operates through Thar Commercial Finance Private Limited.
The legal entities of Epizyme currently have 4 directors, including Yatin Ajitrai Mankad, Vivek Jayesh Thar, Chintan Hitendra Shah and others.